Search Results

Press Releases

Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal

February 25, 2025

·

4 min read

Press Releases

Apotex acquires US rights to PROVIGIL® (modafinil) and NUVIGIL® (armodafinil)

January 9, 2025

·

2 min read

Apotex to Participate in the Jefferies Global Healthcare Conference 2024

Apotex Inc. announced that Allan Oberman, President & CEO, will be presenting at the Jefferies Healthcare Conference on Wednesday, June 5th, 2024 at 9:00 am EST in New York, NY.

June 4, 2024

·

1 min read

BioMidwest

Apotex Corp. Launches Generic Fertility Treatment Injectable Cetrorelix® in the United States

Apotex Corp. announced the launch of Cetrorelix Acetate for Injection 0.25mg, a generic version of Cetrotide® in the United States.

May 14, 2024

·

1 min read

Deals

Apotex to Acquire Searchlight Pharma, a Canadian Specialty Branded Pharmaceutical Leader

Canada’s largest pharmaceutical company, Apotex Inc. and Searchlight Pharma Inc. (“Searchlight”), one of Canada’s fastest growing companies, announced today that they have reached an agreement whereby Apotex will acquire Searchlight.

April 2, 2024

·

4 min read

Deals

Apotex Completes Acquisition of Searchlight, a leading Canadian-based Specialty Innovative Branded Pharmaceutical Company

TORONTO, June 3, 2024 /PRNewswire/ - Apotex Inc. announced the successful completion of its acquisition of Searchlight Pharma Inc., a leading Canadian specialty innovative branded pharmaceutical company.

June 3, 2024

·

2 min read

Apotex Inc. to Present at the 2024 Bloom Burton & Co. Annual Healthcare Investor Conference

Apotex Inc. announced today that Allan Oberman, President & CEO, will be presenting at the 2024 Bloom Burton & Co. Annual Healthcare Investor Conference on Wednesday, April 17th, 2024 at 11:30 am EST.

April 16, 2024

·

1 min read

Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products

Harrow, Inc. and Apotex Inc. jointly announced an exclusive out-licensing agreement under which Apotex will market and distribute VERKAZIA® and over-the-counter Cationorm® PLUS in the Canadian market, and concurrently, pursue market approval in Canada for VEVYE®, IHEEZO®, and ZERVIATE®.

February 15, 2024

·

5 min read

Press Releases

Apotex Corp. is the first generic manufacturer to launch dasatinib tablets in the United States

September 4, 2024

·

1 min read

BioMidwest

Apotex Corp. Launches Teriparatide Injectable for Osteoporosis Treatment in the United States

Apotex Corp. announced the launch of Teriparatide Injection, a single-patient-use pre-filled pen used for the treatment of osteoporosis in the United States.

November 21, 2023

·

1 min read